CL2016002283A1 - Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición. - Google Patents

Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición.

Info

Publication number
CL2016002283A1
CL2016002283A1 CL2016002283A CL2016002283A CL2016002283A1 CL 2016002283 A1 CL2016002283 A1 CL 2016002283A1 CL 2016002283 A CL2016002283 A CL 2016002283A CL 2016002283 A CL2016002283 A CL 2016002283A CL 2016002283 A1 CL2016002283 A1 CL 2016002283A1
Authority
CL
Chile
Prior art keywords
composition
cysteine
iii
carrier
group
Prior art date
Application number
CL2016002283A
Other languages
English (en)
Inventor
Ronan Power
Zi-Jian Lan
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/855,128 external-priority patent/US9642874B2/en
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of CL2016002283A1 publication Critical patent/CL2016002283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UNA COMPOSICIÓN QUE COMPRENDE POR LO MENOS TRES DIFERENTES COMPUESTOS SELECCIONADOS DEL GRUPO QUE CONSISTE DE 5’-METILSELENOADENOSINA, Se-ADENOSIL-L-HOMOCISTEÍNA, GAMA-GLUTAMIL-METILSELENO-CISTEÍNA, UN COMPUESTO DE LA FÓRMULA (I), (II) O (III) DEFINIDAS Y UN PORTADOR PARA TRATAR LA DIABETES; COMPOSICIÓN.
CL2016002283A 2015-09-15 2016-09-09 Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición. CL2016002283A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/855,128 US9642874B2 (en) 2014-03-14 2015-09-15 Compositions of selenoorganic compounds and methods of use thereof
PCT/US2015/050476 WO2017048252A1 (en) 2015-09-15 2015-09-16 Compositions of selenoorganic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CL2016002283A1 true CL2016002283A1 (es) 2017-03-17

Family

ID=56920509

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002283A CL2016002283A1 (es) 2015-09-15 2016-09-09 Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición.

Country Status (7)

Country Link
EP (1) EP3144001B1 (es)
CA (1) CA2939592C (es)
CL (1) CL2016002283A1 (es)
CO (1) CO2016001839A1 (es)
IL (1) IL247645A0 (es)
PE (1) PE20170500A1 (es)
WO (1) WO2017048252A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545822A (zh) * 2017-05-19 2019-12-06 全技术公司 药剂、组合物及其相关方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
JP2004538240A (ja) 2000-03-31 2004-12-24 パーデュー・リサーチ・ファウンデーション ホスホラミデートおよびそのための方法
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
WO2003095665A2 (en) 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Pmea and pmpa cyclic producing synthesis
EP2223927B1 (en) 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
US8865763B2 (en) * 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
CN101073584B (zh) * 2005-10-14 2012-10-10 全面技术公司 改变细胞功能的方法和组合物
US20080107755A1 (en) * 2006-04-24 2008-05-08 Alltech, Inc. Methods and compositions for altering cell function
US8796241B2 (en) * 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
WO2013151975A1 (en) * 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CA2903845C (en) * 2013-03-15 2022-08-23 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
DK3116511T3 (da) * 2014-03-14 2020-11-23 Alltech Inc Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
IL247645A0 (en) 2017-01-31
CO2016001839A1 (es) 2018-03-20
EP3144001A1 (en) 2017-03-22
EP3144001B1 (en) 2021-08-11
WO2017048252A1 (en) 2017-03-23
CA2939592C (en) 2024-05-28
CA2939592A1 (en) 2017-03-15
PE20170500A1 (es) 2017-05-11

Similar Documents

Publication Publication Date Title
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2018000429A1 (es) Moduladores de la expresión de kras
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20160419A (es) Nuevos compuestos biciclicos
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CY1123194T1 (el) Νεες αντιβακτηριακες ενωσεις
EA201790064A1 (ru) Пестицидные композиции
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
UA120058C2 (uk) Пестицидні композиції
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2018000560A1 (es) Mezclas biocidas
IL285088A (en) Cannabinoid containing composition, methods of preparation and use thereof
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina